Hong Kong Exchanges and Clearing Limited data shows that on August 13, INNOGEN-B (02591) experienced a significant position change, with a total deposit market value of 1.89 billion Hong Kong dollars, representing 6.32% of the total shares. The company's shareholders deposited 26.5564 million shares into Haitong International Securities, increasing their stake by 6.32%.

For the fiscal year ending December 31, 2025, INNOGEN-B reported group revenue of approximately 131.5 million yuan, primarily from the sale of Yisupagluptide alpha in China. The company recorded a net loss of 341 million yuan, widening by 95.4% year-over-year, with a basic loss per share of 0.79 yuan.